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Abstract (196/250) 39 
Staphylococcus aureus is a notorious human bacterial pathogen with considerable 40 
capacity to develop antibiotic resistance. We have observed that human infections 41 
caused by highly-drug resistant S. aureus are more prolonged, complicated and difficult 42 
to eradicate. Here, we describe a novel metabolic adaptation strategy used by clinical 43 
S. aureus strains that leads to resistance to the last-line antibiotic, daptomycin, and 44 
simultaneously impacts host innate immunity. This response was characterized by a 45 
change in anionic membrane phospholipid composition induced by point mutations in 46 
the phospholipid biosynthesis gene, cls2, encoding cardiolipin synthase. Single cls2 47 
point mutations were sufficient for daptomycin resistance, antibiotic treatment failure 48 
and persistent infection. These phenotypes were mediated by enhanced cardiolipin 49 
biosynthesis, leading to increased bacterial membrane cardiolipin and reduced 50 
phosphatidylglycerol. The changes in membrane phospholipid profile led to 51 
modifications in membrane structure that impaired daptomycin penetration and 52 
membrane disruption. The cls2 point mutations also allowed S. aureus to evade 53 
neutrophil chemotaxis, mediated by the reduction in bacterial membrane 54 
phosphatidylglycerol, a previously undescribed bacterial-driven chemoattractant. 55 
Together, these data illustrate a novel metabolic strategy used by S. aureus to 56 
circumvent antibiotic and immune attack, and provide crucial insights into membrane-57 
based therapeutic targeting of this troublesome pathogen.  58 
Keywords: S. aureus, daptomycin, cardiolipin, phosphatidylglycerol, neutrophils 59 
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Significance Statement (109/120) 61 
Staphylococcus aureus is one of the most significant human bacterial pathogens that 62 
has the capacity to cause serious infections and become highly resistant to antibiotics. 63 
In this study, we identified a metabolic adaptation mechanism used by S. aureus to 64 
simultaneously circumvent killing by one of the last-line anti-staphylococcal antibiotics, 65 
daptomycin, and attack from host innate immune cells. This process led to enhanced 66 
bacterial survival and was mediated by a change in bacterial membrane phospholipid 67 
composition sufficient to impair daptomycin membrane penetration and significantly 68 
impact neutrophil chemotactic responses. These results highlight the importance of 69 
bacterial membrane lipid adaptation in bacterial pathogenesis, and provide crucial 70 
insights into potentially novel therapeutic targeting.  71 
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\body 72 
Introduction 73 
Staphylococcus aureus is one of the most important human bacterial pathogens, with a 74 
worldwide distribution and an ability to cause infection of almost any human tissue (1). 75 
Effective treatment of staphylococcal infections has been hampered by the emergence 76 
of antibiotic resistance, leading to increased reliance on last-line antibiotics such as 77 
daptomycin (2). Daptomycin is a cyclic lipopeptide antibiotic that interacts with 78 
bacterial cell membranes but the precise mechanisms of action remain elusive (3). 79 
Notably, human infections caused by daptomycin-resistant S. aureus have been 80 
associated with persistent and complicated infections (2, 4). We and others have 81 
recently shown that clinically-derived daptomycin-resistant isolates caused persistent 82 
infections in non-mammalian and murine septicaemia models (5, 6), raising the 83 
question about the correlation between daptomycin resistance, immune evasion and 84 
bacterial survival in vivo (5, 6).  85 
 86 
Bacteria have evolved highly conserved mechanisms mediating adaptation and 87 
maintenance of membrane integrity to defend against host microbicidal peptides (7, 8). 88 
Mutations in genes related to phospholipid biosynthesis are consistently reported in 89 
Gram-positive bacteria resistant to daptomycin (4). The most abundant phospholipid 90 
found in Gram-positive bacterial membranes, including staphylococcal membranes, is 91 
phosphatidylglycerol (PG). PG can be converted to cardiolipin (CL) and lysyl-92 
phosphatidylglycerol (L-PG) by the enzymes cardiolipin synthase (Cls) and multiple 93 
peptide resistance factor (MprF), respectively (9-11). Gain-of-function mutations in 94 
MprF have been associated with daptomycin resistance (8, 9, 12). Most human bacterial 95 
pathogens have a Cls homolog that catalyzes condensation of two PG molecules to 96 
yield one CL and one glycerol molecule (13). In S. aureus, there are two cls genes, with 97 
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cls2 encoding the major CL synthase (10, 11). Thus far, the bacterial membrane 98 
adaptation response to antibiotic and innate immune exposure in humans is poorly 99 
understood.  100 
 101 
Neutrophils form one of the most fundamental host innate immune effectors against 102 
bacterial pathogens, including S. aureus (14). The clinical significance of neutrophils 103 
is well illustrated by the predisposition to severe and recurrent staphylococcal infections 104 
in patients with functional or quantitative neutrophil deficiencies (15). Neutrophil 105 
recruitment to the site of infection caused by Gram-positive bacteria is often mediated 106 
by bacterial-driven chemoattractants such as formylated peptides and phenol soluble 107 
modulins, or by endogenous cytokines (eg. IL-8) released from host cells (16, 17). In 108 
response, bacteria have evolved mechanisms that interfere with neutrophil chemotaxis, 109 
including chemotaxis inhibitory protein of S. aureus (CHIPS) and formyl peptide 110 
receptor-like 1 inhibitor (FLIPr) (18, 19). Deepening our understanding of how bacteria 111 
evolve during human infection to simultaneously circumvent key innate immune 112 
effectors and antibiotic selection pressure is crucial in our pursuit of novel therapeutic 113 
strategies.     114 
  115 
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RESULTS 116 
 117 
Mutations in S. aureus cardiolipin synthase lead to the evolution of daptomycin 118 
resistance and antimicrobial failure 119 
We have previously collected and reported on S. aureus isolates from nine patients with 120 
bloodstream infection who were all treated with daptomycin (4). Samples were 121 
collected as soon as the infection was detected and later in infection when resistance to 122 
daptomycin and treatment failure was evident (4). All patients had persistent bacteremia 123 
and complicated infections involving heart valves, bone and joints, and deep soft-124 
tissues (4). Whole genome sequencing of the nine paired samples identified non-125 
synonymous point mutations in cls2 in daptomycin-resistant isolates, which were 126 
tightly positioned in the two predicted N-terminal transmembrane domains encoded by 127 
cls2, resulting in A23V, T33N, L52F and F60S amino acid substitutions (Fig. 1A) (4). 128 
To study these nucleotide changes in cls2, independent of other mutations observed in 129 
the clinical daptomycin-resistant strains, allelic replacement experiments were 130 
performed to introduce the individual point mutations into a daptomycin-susceptible 131 
clinical isolate (A8819) producing A8819Cls2A23V, A8819Cls2T33N and A8819Cls2L52F 132 
(Table S1). Several attempts to generate the F60S substitution were unsuccessful. 133 
Daptomycin susceptibility was most perturbed with the T33N mutation (A8819Cls2T33N), 134 
which led to a minimum inhibitory concentration (MIC) of daptomycin similar to that 135 
observed in our clinical resistant isolates (MIC 2 μg/ml) compared to the susceptible 136 
parent strain (MIC 0.5 μg/ml) (Table S1). This magnitude rise in MIC of daptomycin 137 
has been associated with therapeutic failure and poor patient outcomes (2), confirming 138 
the significance of the increase. Chromosomal repair of the T33N mutation 139 
(A8819Cls2T33NN33T) restored daptomycin susceptibility back to wild-type levels (MIC 140 
0.5 μg/ml) (Table S1). L52F and A23V mutations also increased MICs of daptomycin 141 
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but to a lesser degree (up to 1 μg/ml) (Table S1).  142 
 143 
To assess the functional impact of the reduced daptomycin susceptibility with the cls2 144 
mutations, we performed daptomycin treatment assays (Fig. 1B). Daptomycin 145 
concentrations (2 μg/ml and 4 μg/ml) were chosen to mimic free daptomycin 146 
concentration observed in deep tissues and bones under standard human dosing (20, 147 
21). Using a concentration of 2 μg/ml, we showed that daptomycin was rapidly 148 
bactericidal (≥ 3 log10 reduction in colony forming units [CFU]) against all strains over 149 
8 hours, however significant regrowth occurred back to the starting inocula by 24 hours 150 
for A8819Cls2T33N and A8819Cls2L52F (Fig. 1B). In contrast, killing to undetectable levels 151 
was seen for the daptomycin-susceptible parent strain (A8819) and the T33N repaired 152 
strain (A8819Cls2T33NN33T). Similar findings were observed with daptomycin 153 
concentrations up to 4 μg/ml (Fig. S1). Daptomycin treatment failure with 154 
A8819Cls2T33N and A8819Cls2L52F directly correlated with progressive resistance, with an 155 
MIC of daptomycin increasing up to 4 μg/ml, suggesting that additional adaptation 156 
occurred under daptomycin exposure (Fig. 1C). Together, these data show that as seen 157 
in patients, the observed cls2 point mutations genetically predisposed S. aureus to 158 
resistance evolution and therapeutic failure under antibiotic selection.  159 
 160 
Amino acid substitutions in S. aureus cardiolipin synthase enhance cardiolipin 161 
biosynthesis and alter bacterial membrane phospholipid composition 162 
To determine the impact of the clinically derived cls2 point mutations on membrane 163 
phospholipid composition, we extracted total lipids from the daptomycin-susceptible 164 
clinical strain (A8819), the three cls2 point mutants (A8819Cls2T33N, A8819Cls2A23V, 165 
A8819Cls2L52F) and the repaired strain (A8819Cls2T33NN33T). We first assessed lipid 166 
profiles using thin-layer chromatography (Fig. S2A), which showed that relative to 167 
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A8819, the three cls2 point mutants had an increase in membrane CL content and a 168 
reduction in PG, with no change in L-PG. A time-course lipid analysis over bacterial 169 
growth phases supported these findings (Fig. S2B, C). The concentration of individual 170 
phospholipid species was then quantified using liquid chromatography coupled with 171 
mass spectrometry (LC-MS). Consistent with the TLC analysis, the percentage of CL 172 
among total phospholipids increased significantly in the three cls2 point mutants 173 
compared to A8819, whereas the PG content decreased significantly (Fig. 2A). None 174 
of the cls2 mutations impacted on L-PG. Overall, the membrane phospholipid changes 175 
were most pronounced for A8819Cls2T33N (Fig. 2A), which paralleled the magnitude of 176 
daptomycin resistance. Importantly, as seen with daptomycin susceptibility, repair of 177 
the T33N mutation restored the membrane phospholipid profile back to wild-type levels 178 
(Fig. 2B and Fig. S2D). The increase in CL in the cls2 point mutants was not secondary 179 
to an increase in cls2 transcription or Cls2 membrane quantity, and Cls2 membrane 180 
localization was unchanged compared to A8819 (Fig. S3A-C).   181 
 182 
To test whether the cls2 mutations increased cardiolipin synthesis activity in vivo, 183 
bacteria were metabolically labelled with 13C-glycerol, which is incorporated into the 184 
glycerol backbone and head group of PG and CL (Fig. S4A-C). The formation of 185 
complex PG or CL mass isotopomers (+3, +6 and +9) by LC-MS can then be used to 186 
measure de novo biosynthesis of these phospholipids (Fig. S4A-C). Compared to wild-187 
type, we showed that CL biosynthesis significantly increased over time in our T33N 188 
mutant strain (Fig. 2C) and this was mirrored by a reduction in PG biosynthesis (Fig. 189 
2D). Given that PG is both a metabolic end-product and precursor for CL, these results 190 
suggest that CL is synthesized from a sub pool of PG in the mutant to account for the 191 
different degree of 13C-labelling. No difference in biosynthesis of L-PG was observed 192 
(Fig. 2E). Together, these data confirm that clinically relevant Cls2 amino acid 193 
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substitutions caused enhanced membrane cardiolipin biosynthesis that was proportional 194 
to the degree of antibiotic resistance. 195 
 196 
Changes in S. aureus membrane composition blocks daptomycin mediated lipid 197 
extraction, membrane penetration and disruption 198 
To assess the impact of Cls2-mediated lipid changes on daptomycin-membrane 199 
interactions, we reconstituted Gram-positive bacterial bilayer membranes immobilised 200 
on a planar surface for characterization by neutron reflectometry (NR) (22, 23) (Fig. 201 
S5A). The bilayers were incubated with isotopic solvents (D2O and H2O) and the NR 202 
profiles of wild-type and A8819Cls2T33N were modelled simultaneously to analyze the 203 
bilayer structures (Fig. 3A-B). The cardiolipin-rich membrane caused by the Cls2 T33N 204 
amino acid substitution was thicker compared to the wild-type membrane (57.8 ± 3.7 205 
Å versus 49.4 ± 3.3 Å, respectively) (Fig. S5B, Table S2-3, Fig. 3C-D). Despite the 206 
overall differences in membrane thickness, the cell surface charge was similar, and 207 
using super-resolution microscopy of cell surface bound fluorescent daptomycin, we 208 
showed that the level and distribution of daptomycin binding on A8819Cls2T33N cell 209 
surface was similar to A8819 (Fig. S6A-D). These data support the hypothesis that 210 
structural modification of the membrane impairs daptomycin penetration and 211 
membrane disruption rather than initial binding. 212 
 213 
Using NR, we then characterised the impact of the observed membrane changes on 214 
daptomycin interactions. Daptomycin treatment at 2, 4 and 8 μg/ml significantly shifted 215 
the fringe of the NR curves of the wild-type membranes in a concentration dependent 216 
manner (Fig. 3A. arrows), indicating extraction and solubilisation of the membrane by 217 
daptomycin. In contrast, there was a less pronounced change in reflectivity for the 218 
cardiolipin-rich, daptomycin-resistant A8819Cls2T33N membrane (Fig. 3B). Analysis of 219 
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the NR curves showed that at a daptomycin concentration of 2 μg/ml, the lipid volume 220 
fraction of the wild-type membrane was reduced, and no daptomycin was seen within 221 
the membrane consistent with a lipid extraction mechanism (24) (Table 1, Table S4). 222 
At a higher daptomycin concentration (4 μg/ml), antibiotic membrane penetration was 223 
evident, extending through the bilayer and causing dislocation of acyl-chains (Table 1, 224 
Table S4). At the highest concentration (8 μg/ml), the membrane was completely 225 
solvated by daptomycin, with a substantial decrease in the lipid volume fraction from 226 
86.5% to 26.6% (Table 1, Table S4). For the thicker, cardiolipin rich, A8819Cls2T33N 227 
membrane, only mild lipid extraction was observed at 2, 4 and 8 μg/ml with the lipid 228 
volume fraction only reducing from 78.5% to 62.8% (Table1, Table S5). The 229 
A8819Cls2T33N membrane resisted daptomycin penetration and remained intact (Table 1, 230 
Table S5).  231 
 232 
To further define the daptomycin-membrane interaction, we then used small-angle 233 
neutron scattering (SANS), which provided information on the daptomycin aggregation 234 
characteristics within the bilayer membranes under physiologically relevant conditions 235 
(25). Consistent with our NR data, at a clinically relevant daptomycin concentration of 236 
4 μg/ml, we observed daptomycin penetrate and form aggregates straddling the bilayer 237 
membrane for wild-type (A8819) but not for the A8819Cls2T33N membranes (Fig. 3E, 238 
and F). These data also concur with our bacterial killing data, which showed complete 239 
bacterial killing for wild-type A8819 but therapeutic failure toward A8819Cls2T33N (Fig. 240 
S1). Using established core-shell and hollow-cylinder models to characterise the 241 
daptomycin aggregates (25), it was estimated that daptomycin constituted a 28 ± 0.86 242 
Å radius spherical micelle structure within the membrane bilayer (Fig. S7). Taken 243 
together, these results show that S. aureus adapts during treatment with daptomycin in 244 
human infections by increasing its cardiolipin membrane content leading to a thicker 245 
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membrane that resists daptomycin lipid extraction, and membrane penetration and 246 
disruption, promoting bacterial survival.  247 
 248 
Cls2 amino acid substitutions impair neutrophil recruitment in vivo and promote 249 
bacterial survival 250 
Apart from impairing daptomycin-membrane interactions, we hypothesised that the 251 
altered bacterial membrane phospholipid profile caused by cls2 point mutations may 252 
impact on S. aureus – host interactions. Neutrophils are the dominant innate immune 253 
cell for controlling S. aureus infection (14, 15). To interrogate neutrophil behaviour in 254 
vivo and in real-time with high resolution, we utilised the vertebrate zebrafish (Danio 255 
rerio) model system (26). In common with humans, zebrafish have cellular and soluble 256 
immune arms, and complex tissue environments that enable a mechanistic 257 
understanding of human infectious diseases (26, 27). To assess neutrophil trafficking 258 
and recruitment to a localized soft tissue staphylococcal infection, we used transgenic 259 
embryos with red fluorescent neutrophils (Tg[lyz:dsRed]) (28) that were infected into 260 
the somatic muscle with GFP-expressing S. aureus (Fig. 4A). Notably, neutrophil 261 
recruitment to the localized infection site was significantly compromised for infection 262 
with the three cls2 point mutants compared to infection by A8819 after 6 hours post-263 
infection (Fig. 4B,C). Mutation repair for the T33N strain (A8819Cls2T33NN33T) was 264 
sufficient to restore neutrophil recruitment back to wild-type (A8819) infection levels 265 
(Fig. 4D). This attenuated neutrophil response impacted bacterial clearance, with more 266 
persistent infection observed with A8819Cls2T33N compared to the wild-type and repaired 267 
strains (Fig. 4E). To further validate the observed neutrophil migration findings in 268 
zebrafish, we assessed human neutrophil migration within an ex-vivo assay. As shown 269 
in Fig. 4F, significantly less human neutrophil recruitment was observed with 270 
A8819Cls2T33N compared to the wild-type strain. Mutation repair of the T33N mutant 271 
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(A8819Cls2T33NN33T) caused similar neutrophil recruitment as wild-type (Fig. 4F). These 272 
results indicated that the Cls2 amino acid substitutions equipped S. aureus with the 273 
ability to circumvent neutrophil recognition and response, leading to a persistent 274 
infection as observed in patients and animal models (2, 5, 6). 275 
 276 
Compositional changes of membrane phospholipids resulted in reduced 277 
neutrophil recruitment in zebrafish 278 
To investigate the contribution of the S. aureus bacterial membrane to neutrophil 279 
evasion, total lipids were extracted from each of the cls2 mutant and the daptomycin-280 
susceptible parent (A8819) and repaired strains. Liposomes were then processed and 281 
injected into the otic vesicle of zebrafish (Fig. 4A, white circle). The otic vesicle is 282 
normally devoid of leukocytes and is relatively confined, preventing dispersion of the 283 
liposomes (29). As shown in Fig. 5A, and similar to that seen with infection of live, 284 
whole bacterial cells (Fig. 4B-D), the liposomes from the three cls2 point mutants were 285 
significantly attenuated in inducing neutrophil recruitment compared to liposomes from 286 
A8819 and the T33N repaired strain (A8819Cls2T33NN33T), suggesting that altered anionic 287 
phospholipid composition may be responsible for the immune evasion. To determine 288 
the phospholipid driver of this S. aureus evasion response, purified PG and CL that 289 
were free of DNA, peptidoglycan, wall-teichoic acid, and lipoteichoic acid from A8819 290 
cells (Fig. S8) were processed to form liposomes. Injection of the PG- and CL-specific 291 
liposomes into the otic-vesicle of zebrafish embryos showed that PG liposomes induced 292 
substantial neutrophil recruitment whereas the recruitment of neutrophils by CL 293 
liposomes was comparable to the PBS control (Fig. 5B,C). These data suggest that PG 294 
is the major bacterial-mediated phospholipid driver of neutrophil chemoattraction, and 295 
the S. aureus adaptation response to daptomycin represents a novel bacterial membrane 296 
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based stealth strategy to simultaneously evade an antibiotic and a key innate immune 297 
effector cell to promote survival within a host.  298 
  299 
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DISCUSSION 300 
S. aureus has evolved a wealth of strategies to optimise its survival in various host 301 
niches and under nocuous selection pressures (30). Here, we report a new metabolic 302 
resistance mechanism used by S. aureus to prevent membrane lysis by the last line anti-303 
staphylococcal antibiotic, daptomycin. Single amino acid substitutions in cardiolipin 304 
synthase 2 led to a significant increase in the bacterial membrane CL/PG ratios due to 305 
enhanced cardiolipin biosynthesis, which led to a thicker membrane that resisted 306 
daptomycin penetration and membrane disruption. Intriguingly, this adaption also led 307 
to immune evasion. Specifically, we showed that membrane PG acted as a bacterial-308 
driven neutrophil chemoattractant and, in the context of cls2 point mutations, reduced 309 
PG membrane content led to less neutrophil trafficking to a localized site of infection 310 
and prolonged bacterial survival.  311 
 312 
Recent studies on the interactions between daptomycin and bacterial membranes have 313 
used indirect methodological approaches such as measuring permeability loss of 314 
liposomes exposed to daptomycin using a fluorescence assay, and membrane systems 315 
that are less relevant to Gram-positive bacteria, particularly using phosphatidylcholine 316 
(PC) and not L-PG (31). It was shown that the addition of cardiolipin to 10% of total 317 
lipids (using a PC/PG membrane system) was sufficient to prevent daptomycin 318 
interaction with membranes (31), however we have clearly shown that our daptomycin 319 
susceptible clinical strain (A8819) already has a greater percent of cardiolipin than 10% 320 
(Fig. 2A), suggesting the possibility of discordance between clinically relevant 321 
membranes. More recently, alteration of membrane curvature and diverting daptomycin 322 
binding, or interference with fluid membrane microdomains have been proposed using 323 
the model organism Bacillus subtilis or enterococcal strains (7, 32, 33). However, the 324 
phospholipid membrane composition of these organisms is different to S. aureus, and 325 
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daptomycin-membrane interactions appear to be bacterial-species dependent. For 326 
example, daptomycin has an irregular membrane binding pattern in B. subtilis and 327 
Enterococcus, with a particular predilection for the division septum (7, 32, 33), whereas 328 
we have observed universal distribution of daptomycin on S. aureus membranes (Fig. 329 
S6C-D).  330 
 331 
Here, we have reconstituted clinically relevant S. aureus membranes and have provided 332 
the first direct structural analysis of daptomycin-membrane interactions. The scattering 333 
of free neutrons by matter provides excellent structural detail and this experimental 334 
approach has only recently been used to study biological membranes (25, 34). We used 335 
unsaturated phospholipids with complex head group composition to reconstitute the 336 
membranes, and the surface coverage achieved for the wild-type membranes was 86.5% 337 
(Table 1), which is higher than what has been previously reported using unsaturated 338 
phospholipids with similar techniques (35). Using SANS and NR, we identified three 339 
distinct modes of action of daptomycin on the membrane. At lower concentrations (2 340 
μg/ml), lipid extraction occurred and caused lesions in the bilayer membrane, whereas 341 
at higher concentrations (4 μg/ml), daptomycin molecules penetrated into the bilayer 342 
and formed organised micelles. At the highest concentrations (8 μg/ml), the bilayer was 343 
completely solvated by daptomycin. The process of lipid extraction, penetration, 344 
micelle formation and membrane lysis was inhibited in the context of the clinically 345 
derived Cls2 amino acid substitution T33N, which coincided with daptomycin 346 
resistance. Interestingly, the daptomycin molecules still attached to the outer leaflet of 347 
the membrane in the A8819Cls2T33N strain, and this was corroborated with super-348 
resolution imaging of fluorescent daptomycin binding to bacterial cells, but the 349 
daptomycin was functionally impaired due to the barrier created by the thicker CL-rich 350 
membrane. This is an anionic phospholipid driven mechanism of daptomycin resistance 351 
17 
 
and is independent of the charge-based repulsion theory proposed for mprF mutations 352 
that alter L-PG membrane content (4, 12).  353 
 354 
Subversion of host immune surveillance contributes to persistent bacterial infections 355 
(36). Given the importance of neutrophils in eliminating S. aureus (15), we utilized a 356 
transgenic zebrafish line carrying red fluorescent neutrophils to characterize the 357 
interactions between S. aureus and neutrophils in vivo and in real-time during acute 358 
infection. We found that infection with the S. aureus cls2 point mutants compromised 359 
neutrophil recruitment and this was associated with a more prolonged bacterial burden 360 
in the host. This compromised neutrophil migration was further confirmed using human 361 
neutrophils. The purified PG and CL liposomes used for the neutrophil migration 362 
studies were found to be free of DNA, peptidoglycan, lipoteichoic acids and wall-363 
teichoic acids (Fig. S8), suggesting that established bacterial driven neutrophil 364 
chemoattractants for compromised neutrophil migration were not at play (37). We then 365 
focused on the phospholipid membrane components and through injection of purified 366 
CL and PG liposomes into zebrafish, established that PG was a driver for neutrophil 367 
chemotaxis. This provided a mechanistic model whereby Cls2 amino acid substitutions 368 
led to increased cardiolipin synthase activity and increased CL production that was 369 
subsequently causing a reduction in PG. This change in lipid profile not only disturbed 370 
daptomycin-membrane interactions, but also reduced neutrophil chemoattraction to a 371 
localized site of infection, finally resulting in a more persistent infection, which has 372 
been observed in patients and animal models without a clear explanation (2, 5, 6). 373 
Future analyses are still required to investigate the generalization of bacterial PG in 374 
inducing neutrophil migration and if PG acts directly as a chemotactic or indirectly via 375 
activation of endogenous cells. In conclusion, we have characterised a bacterial 376 
metabolic adaptation process that leads to simultaneous evasion of host immune and 377 
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antimicrobial attack, providing important insights for future therapeutic targeting for 378 
this troublesome pathogen.     379 
 380 
Materials and Methods 381 
Media and reagents 382 
Bacterial strains, plasmids, and oligonucleotides used in this study are described in 383 
Table S6. S. aureus and Escherichia coli cells were cultured in heart infusion broth (HI) 384 
(Oxoid) and Luria-Bertani broth with constant shaking at 37 ºC, respectively. 385 
 386 
Genetic manipulation 387 
The vector pIMAY and the Escherichia. coli strain DC10B were used to genetically 388 
manipulate S. aureus isolate A8819 following the published protocol (SI Materials and 389 
Methods) (38).  390 
 391 
Daptomycin susceptibility testing 392 
Broth microdilution MIC testing was performed based on guidelines by the Clinical 393 
and laboratory standards institute (CLSI). Daptomycin MIC > 1 μg/ml is officially 394 
termed daptomycin-nonsusceptible, but was termed daptomycin resistant throughout 395 
the manuscript for clarity. Time-kill assays were performed with an initial bacterial 396 
inoculum of 106 CFU/ml in Mueller-Hinton broth supplemented with 50 mg/litre 397 
calcium and daptomycin. (SI Materials and Methods). 398 
 399 
Lipid analysis by mass spectrometry 400 
Lipids were extracted and analysed using thin-layer chromatography following the 401 
published protocol (10). Lipid species were processed and quantified according to 402 
standard procedures (39). For de novo phospholipid biosynthesis, the metabolic 403 
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labelling was initiated by the addition of glycerol or [13C]-glycerol (Sigma-Aldrich) to 404 
1 mM after bacterial growth from optical density 600nm of 0.4 for 30 minutes at 37 ºC. 405 
Data collected for lipid composition of PG, CL and L-PG with 13C-glycerol 406 
incorporation was analysed using Metaboanalyst (http://www.metaboanalyst.ca) (SI 407 
Materials and Methods).  408 
 409 
S. aureus bilayer membrane formation and neutron reflectometry (NR) 410 
Deposition of the model membrane on the top of a SiO2 surface was performed using a 411 
custom built Langmuir-Blodgett trough (Nima Technology, Conventry, UK) following 412 
published Langmuir–Blodgett (LB) and Langmuir–Schaefer (LS) procedures (22) (SI 413 
Materials and Methods). Synthetic PG (18:1), CL (18:1) and L-PG (18:1) (Avanti Polar 414 
Lipids, Inc) were mixed at the molar ratios of 69:12:19 and 23:60:17 to create A8819 415 
and A8819Cls2T33N symmetric membrane bilayers, respectively.  416 
Specular neutron reflection at solid-liquid interface was carried out on the Platypus 417 
time-of-flight neutron reflectometer at the OPAL 20 MW Multi-purpose Research 418 
Reactor, Lucas Heights, Australia. The final reflectivity (reflected intensity / incident 419 
intensity) is presented as a function of momentum transfer. Analysis of the NR profiles 420 
was performed using MOTOFIT followed by Monte Carlo Analysis to determine 95% 421 
confidence intervals (40). (SI Materials and Methods).  422 
   423 
 424 
Small angle neuron scattering (SANS) 425 
Synthetic PG, CL and L-PG were mixed at the molar ratios of 69:12:19 and 23:60:17 426 
for producing A8819 and A8819Cls2T33N membrane vesicles respectively. The samples 427 
were measured using the small-angle neutron scattering instrument, Quokka, at ANSTO. 428 
(SI Materials and Methods).  429 
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 430 
Zebrafish strains, maintenance and leukocyte enumeration 431 
Wild-type Tübingen and Tg(lyz:DsRed)nz50 zebrafish (28) embryos were maintained in 432 
the Monash University Fish Core facility and infected with S. aureus cells according to 433 
standard protocols (27) (SI Materials and Methods).  434 
 435 
In vitro Transwell chemotaxis assay 436 
Human venous blood was collected from healthy volunteers for isolating neutrophils 437 
with the approval of the Monash University Human Research Ethics Committee. 438 
Chemotaxis assays were performed according to a previously published protocol (41) 439 
(SI Materials and Methods).  440 
 441 
Liposome preparation 442 
Staphylococcal PG or CL were extracted from TLC plates using 443 
chloroform/methanol/water (5:5:1) followed by centrifugation. Liposomes were 444 
prepared following an established protocol (42) (SI Materials and Methods).  445 
 446 
 447 
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Figure Legends 591 
Fig. 1. Impact of Cls2 amino acid substitutions on daptomycin killing and resistance 592 
emergence. (A) The predicted amino acid change in Cls2 by individual cls2 point 593 
mutations. N: amino-terminus. C: carboxyl-terminus. TM: transmembrane domain. 594 
PLD: phospholipase D domain. (B) Time-kill analyses showing quantitative bacterial 595 
counts during exposure to 2 μg/ml daptomycin. Dashed line indicates the detection limit. 596 
Comparison of the area under the curve between mutants and wild-type by one-way 597 
ANOVA (*P < 0.05, **P < 0.01). (C) Daptomycin MIC of staphylococcal cells at each 598 
time point from the time-kill analysis. Error bars represent mean ±  SEM, three 599 
independent experiments. 600 
 601 
Fig. 2. Impact of cls2 point mutations on membrane phospholipid profiles. (A) The 602 
molar ratio of PG, CL, and L-PG among total phospholipids determined by LC-MS. (B) 603 
Repair of Cls2 T33N (T33NN33T) restored membrane phospholipid profiles to wild-604 
type levels. Phospholipid biosynthesis was assessed after treatment with 13C-glycerol. 605 
(C) The ratios of 13C-CL, (D) 13C-PG and (E) 13C-L-PG (all isotopomers) among total 606 
lipid content were determined by LC-MS. Mean ± SD, three independent experiments. 607 
*P < 0.05, **P < 0.01 and ***P < 0.001, one-way ANOVA. n.s. non-significant. 608 
Student’s t test was used to compare T33N to WT (C-E). 609 
 610 
Fig. 3. Daptomycin-membrane interactions. The neutron reflectivity profiles (symbols) 611 
and fits (lines) of A8819 (A) and A8819Cls2T33N (B) membrane models in D2O and H2O 612 
are shown. The NR profiles in H2O are offset for clarity. The arrows indicate fringe 613 
shifts of NR profiles. The molecular models of reconstituted A8819 (C) and 614 
A8819Cls2T33N (D) membranes show a thicker, but more CL-rich membrane structure 615 
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(with CL in yellow, PG in red, and L-PG in blue). Small angle neutron scattering 616 
profiles measured for A8819 (E) and A8819Cls2T33N (F) membranes treated with and 617 
without daptomycin (4μg/ml). The arrow indicates the lipid bilayer whilst the star 618 
indicates the Bragg peak as the sign of micelle formation. 619 
 620 
Fig. 4. Impact of Cls2 amino acid substitutions on neutrophil recruitment. (A) 621 
Schematic of a 48 h post-fertilization (hpf) zebrafish showing the S. aureus injection 622 
sites. Rectangle: somatic muscle. White circle: the otic vesicle. Scale bar = 250μm. (B) 623 
Representative images of localized sites of infection with S. aureus strains at 6 h post-624 
infection. (C) The number of emigrated neutrophils to the localized site of infection. 625 
For WT, n = 22; A23V, n = 29; T33N, n = 34; L52F, n = 27, pooled from four 626 
independent experiments. (D) Neutrophil recruitment was restored to wild-type levels 627 
by the repaired strain A8819Cls2T33NN33T. For PBS, n = 12; WT, n = 21; T33N, n = 22; 628 
T33NN33T, n = 23, pooled from three independent experiments. (E) The bacterial 629 
burden in zebrafish after a somatic muscle infection. Error bars represent mean + SEM, 630 
three independent experiments (***P < 0.001 compared to WT and T33NN33T, chi-631 
square test for trend). (F) Human neutrophil recruitment was assessed using a Transwell 632 
system, with neutrophils and bacterial cells in the top and bottom wells respectively. 633 
Five independent experiments. For (C, D, and F), error bars represent mean ± SEM. 634 
*P < 0.05, ***P < 0.001 compared to WT, Kruskal-Wallis test. 635 
 636 
Fig. 5. Impact of bacterial membrane phospholipids on neutrophil migration in vivo. (A) 637 
Quantification of emigrated neutrophils into the zebrafish otic vesicle at 6 h after 638 
injection of liposomes constituted from S. aureus membrane phospholipids. For PBS, 639 
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n = 14; WT, n = 28; A23V, n = 26; T33N, n = 24; L52F, n = 24; T33NN33T, n = 17, 640 
pooled from four independent experiments. (B) Representative images of zebrafish otic 641 
vesicles (red circles) injected with purified PG or CL liposomes, with quantification of 642 
emigrated neutrophils (C). For PBS, n = 10; PG, n = 17; CL, n = 17, pooled from three 643 
independent experiments. Error bars represent the mean ± SEM. *P < 0.05, **P < 0.01 644 
and ***P < 0.001 compared to PBS for (A) and (C), one-way ANOVA.  645 
 646 
 647 
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